Minimum Offering: $1.25M
Maximum Offering: $5M
$5,000 (1000 shares)
Pre Money Valuation: $50M
Instrument: Common Stock
Deadline: Dec 31, 2021
Breast and cervical cancers are the most common and lethal cancers in the world for women. Globally, 90% of women have limited access to early detection— most get diagnosed at stage 3 and 4, with poor prognosis.
We are a women’s health company laser-focused on preventive oncology. We design, develop and commercialize hand-held, non-invasive, effective and easy to use medical devices and app-based platforms - built for mass adoption in B2B settings and soon for the consumer’s self-use, at home (B2C).
We’re commercializing and developing new breakthrough sensor technologies that can detect tumors and lesions instantly at the point of care, without requiring expert interpretation, virtually in any setting and without any pain or radiation.
breakthrough products designed for massive scale across B2B & B2C markets.
Award-winning, patent-pending, radiation-free, ultra-portable wireless device, usable by lay health-workers to identify and document small, non-palpable lumps, quickly and easily, at the point-of-care.
FDA cleared. In commercialization.
AI enabled mobile colposcopefor cervical cancer screening. CervAIcal is a high-quality, wireless universal cervical examination assistant that goes where the patients are. Ongoing Pilots.
World's first, at home
breast health monitoringdevice / app / platformbuilt with iBreastExam technology
Commercial launch expected in 2022
As we continue developing and commercializing our proprietary products, UE LifeSciences has secured major research milestones, commercial partnerships, multiple international awards, and press features.
examined and help diagnose 200+ cancer cases
Global Agreement in April 21 to market & scale iBreastExam
since 2018; from 750 devices and 1.5M scans
with regulatory approvals & distribution channels
Validations & Publications by Global Experts & Clinical Advisors
ACOG TV, ACOG 2021 (American College of Obstetricians and Gynecologists Annual Meeting)
Innovative Health Technology
World Health Organization, Compendium of innovative health technologies for low-resource settings
Drop us a line and stay in touch!
People & Plans
Our team collectively brings together over 100 years of med-tech commercialization experience. We are backed by reputed investors and advisors.
USA | India | Malaysia
Backers & Partners
Enabling our Vision
Co-Founder & CEO
Co-Founder & CTO
Dreams in Action
Women’s Health (or FemTech) set to be a $50B global market by Yr 2025.Tele-Health is $22 billion US market in 2020, growing at a CAGR of 28%.Increasing adoption of wearables, IoT and other med-devices at home.
UE LifeSciences Inc. Copyright © 2021 | Terms & Conditions